pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

被引:0
|
作者
Kobayashi, K
Bouscarel, B
Matsuzaki, Y
Ceryak, S
Kudoh, S
Fromm, H
机构
[1] George Washington Univ, Med Ctr, Div Gastroenterol & Nutr, Washington, DC 20037 USA
[2] Nippon Med Sch, Dept Internal Med 4, Tokyo 113, Japan
[3] George Washington Univ, Dept Biochem & Mol Biol, Washington, DC USA
[4] Univ Tsukuba, Div Gastroenterol, Ibaraki, Osaka, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Irinotecan (CPT-11) and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), are believed to be reabsorbed by intestinal cells and to enter the entero-hepatic circulation, but there is little information to date. Our objective was to investigate the intestinal transport of CPT-11 and SN-38 in correlation with their associated cytotoxicity. Using either isolated hamster intestinal epithelial cells or/and human colon carcinoma HT29 cells, the uptake rates of [C-14]CPT-11 and [C-14]SN-38, both as respective non-ionic lactone form at acidic pH and anionic carboxylate form at basic pH, were investigated by the rapid vacuum filtration technique. The effect of physiologic intestinal luminal pH (6.2-8.0) on the uptake rate and cytotoxicity of SN-38 were estimated by the above method and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, respectively. The lactone forms of CPT-11 and SN-38 were transported passively, while the respective carboxylate form was absorbed actively. Uptake rates of both lactones were significantly higher than those of their carboxylates, Under physiologic pH, the respective uptake rates of CPT-11 and SN-38 were pH sensitive and decreased significantly by around 65%, at pH greater than 6.8. Furthermore, with decreasing pH, a higher uptake rate of SN-38 into HT29 cells correlates with a greater cytotoxic effect (r = 0.987). CPT-11 and SN-38 have absorption characteristics of weakly basic drugs such as short-chain fatty acids, suggesting that alkalization of the intestinal lumen may be critical to reduce their reabsorption and associated side effects. Int. J. Cancer 83:491-496, 1999. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 50 条
  • [21] Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy
    Irie, Kei
    Okada, Akira
    Masuda, Yoshio
    Fukushima, Keizo
    Sugioka, Nobuyuki
    Okuda, Chiyuki
    Hata, Akito
    Kaji, Reiko
    Okada, Yutaka
    Katakami, Nobuyuki
    Fukushima, Shoji
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 865 - 868
  • [22] UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
    Ando, Y
    Saka, H
    Asai, G
    Sugiura, S
    Shimokata, K
    Kamataki, T
    ANNALS OF ONCOLOGY, 1998, 9 (08) : 845 - 847
  • [23] Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
    Karas, Spinel
    Etheridge, Amy S.
    Tsakalozou, Eleftheria
    Ramirez, Jacqueline
    Cecchin, Erika
    van Schaik, Ron H. N.
    Toffoli, Giuseppe
    Ratain, Mark J.
    Mathijssen, Ron H. J.
    Forrest, Alan
    Bies, Robert R.
    Innocenti, Federico
    AAPS JOURNAL, 2020, 22 (03):
  • [24] Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
    Spinel Karas
    Amy S. Etheridge
    Eleftheria Tsakalozou
    Jacqueline Ramírez
    Erika Cecchin
    Ron H.N. van Schaik
    Giuseppe Toffoli
    Mark J. Ratain
    Ron H.J. Mathijssen
    Alan Forrest
    Robert R. Bies
    Federico Innocenti
    The AAPS Journal, 22
  • [25] OATP1B1-MEDIATED HEPATIC UPTAKE OF SN-38, AN ACTIVE METABOLITE OF IRINOTECAN, AND ITS INHIBITION BY UREMIC TOXINS IN HUMANS
    Fujita, K.
    Sugiura, T.
    Okumura, H.
    Umeda, S.
    Nakamichi, N.
    Sasaki, Y.
    Kato, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S32 - S32
  • [26] pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation
    Peikov, V
    Ugwu, S
    Parmar, M
    Zhang, A
    Ahmad, I
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 299 (1-2) : 92 - 99
  • [27] Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide
    Klein, CE
    Gupta, E
    Reid, JM
    Atherton, PJ
    Sloan, JA
    Pitot, HC
    Ratain, MJ
    Kastrissios, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) : 638 - 647
  • [28] An Accurate Assay for Simultaneous Determination of Irinotecan and Its Active Metabolite SN-38 in Rat Plasma by LC with Fluorescence Detection
    Zhang, Ziqiang
    Yao, Jing
    Wu, Xiaotao
    Zou, Jianjun
    Zhu, Jiabi
    CHROMATOGRAPHIA, 2009, 70 (3-4) : 399 - 405
  • [29] A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients
    Denic, Kristina Zoran
    Neuhoff, Sibylle
    Reid, Joel
    Kudget, Rachel
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [30] An Accurate Assay for Simultaneous Determination of Irinotecan and Its Active Metabolite SN-38 in Rat Plasma by LC with Fluorescence Detection
    Ziqiang Zhang
    Jing Yao
    Xiaotao Wu
    Jianjun Zou
    Jiabi Zhu
    Chromatographia, 2009, 70 : 399 - 405